Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISA 2022 | Rationale for anti-amyloid therapy in systemic amyloidosis

Marina Ramirez-Alvarado • 7 Sep 2022
ISA 2022
Amyloidosis Rare Diseases

Marina Ramirez-Alvarado, PhD, Mayo Clinic, Rochester, MN, outlines the kinetic and thermodynamic rationale for anti-amyloid therapy in systemic amyloidosis. This interview took place at the 2022 International Symposium on Amyloidosis (ISA) held in Heidelberg, Germany.

Disclosures

Honorarium from Attralus

More from Marina Ramirez-Alvarado

1:25
The importance of early diagnosis in systemic amyloidosis
Marina Ramirez-Alvarado • 7 Sep 2022
1:15
Closing the gap between basic and clinical research in AL and ATTR amyloidosis
Marina Ramirez-Alvarado • 7 Sep 2022

Related Videos

3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
1:11
Personalized risk assessment for transplantation in primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
1:18
Autologous gene editing using the CRISPR system to treat primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
0:58
Hematological manifestations associated with primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals